View in EDS

Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms.

Saved in:
Bibliographic Details
Title: Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms.
Authors: Abdel-Razeq H; Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan.; School of Medicine, The University of Jordan, Amman 11942, Jordan., Sharaf B; Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan.
Source: Current oncology (Toronto, Ont.) [Curr Oncol] 2026 Jul 14; Vol. 33 (7). Date of Electronic Publication: 2026 Jul 14.
Publication Type: Journal Article; Review
Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42505223
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Abdel-Razeq+H%22">Abdel-Razeq H</searchLink>; Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan.; School of Medicine, The University of Jordan, Amman 11942, Jordan.<br /><searchLink fieldCode="AU" term="%22Sharaf+B%22">Sharaf B</searchLink>; Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502503%22">Current oncology (Toronto, Ont.)</searchLink> [Curr Oncol] 2026 Jul 14; Vol. 33 (7). <i>Date of Electronic Publication: </i>2026 Jul 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22MDPI%22">MDPI </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>9502503 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1718-7729 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211980052%22">11980052 </searchLink><i>NLM ISO Abbreviation: </i>Curr Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42505223
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/curroncol33070421
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Abdel-Razeq H
      – PersonEntity:
          Name:
            NameFull: Sharaf B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 07
              Text: 2026 Jul 14
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1718-7729
          Numbering:
            – Type: volume
              Value: 33
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Current oncology (Toronto, Ont.)
              Type: main
ResultId 1